OVID (Ovid Therapeutics) Shiller PE Ratio: (As of Aug. 12, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OVID Ovid Therapeutics Inc OVID
48 GF Score
Price $2.62
GF Value $13.57
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Ovid Therapeutics Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Ovid Therapeutics  (NAS:OVID) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Ovid Therapeutics Shiller PE Ratio Related Terms


Ovid Therapeutics Shiller PE Ratio Historical Data

* Premium members only.

The historical data trend for Ovid Therapeutics's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ovid Therapeutics Shiller PE Ratio Chart

Ovid Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Ovid Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

OVID vs SGMT, CABA, QTTB: Shiller PE Ratio Comparison

For the Biotechnology subindustry, Ovid Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ovid Therapeutics Shiller PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ovid Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Ovid Therapeutics's Shiller PE Ratio falls into.


OVID
48GF Score
Ovid Therapeutics Inc OVID
Shiller PE Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ovid Therapeutics Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Ovid Therapeutics's E10 for the quarter that ended in Mar. 2026 is calculated as:

For example, Ovid Therapeutics's adjusted earnings per share data for the three months ended in Mar. 2026 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-0.12/330.2130*330.2130
=-0.120

Current CPI (Mar. 2026) = 330.2130.

Ovid Therapeutics Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201606 -0.275 241.018 -0.377
201609 -0.295 241.428 -0.403
201612 -0.386 241.432 -0.528
201703 -1.392 243.801 -1.885
201706 -0.570 244.955 -0.768
201709 -0.380 246.819 -0.508
201712 -0.450 246.524 -0.603
201803 -0.540 249.554 -0.715
201806 -0.530 251.989 -0.695
201809 -0.530 252.439 -0.693
201812 -0.520 251.233 -0.683
201903 -0.460 254.202 -0.598
201906 -0.340 256.143 -0.438
201909 -0.430 256.759 -0.553
201912 -0.350 256.974 -0.450
202003 -0.370 258.115 -0.473
202006 -0.410 257.797 -0.525
202009 -0.280 260.280 -0.355
202012 -0.340 260.474 -0.431
202103 2.530 264.877 3.154
202106 -0.230 271.696 -0.280
202109 -0.170 274.310 -0.205
202112 -0.380 278.802 -0.450
202203 -0.230 287.504 -0.264
202206 -0.210 296.311 -0.234
202209 -0.170 296.808 -0.189
202212 -0.160 296.797 -0.178
202303 -0.190 301.836 -0.208
202306 -0.180 305.109 -0.195
202309 -0.160 307.789 -0.172
202312 -0.210 306.746 -0.226
202403 -0.170 312.332 -0.180
202406 0.120 314.175 0.126
202409 -0.200 315.301 -0.209
202412 -0.130 315.605 -0.136
202503 -0.140 319.799 -0.145
202506 -0.060 322.561 -0.061
202509 -0.170 324.800 -0.173
202512 0.060 324.054 0.061
202603 -0.120 330.213 -0.120

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Ovid Therapeutics (OVID) Overvalued in 2026?

Based on GuruFocus' analysis, Ovid Therapeutics stock appears to be undervalued. The current stock price of $2.62 is trading 80.7% below its estimated GF Value™ of $13.57. GuruFocus considers Ovid Therapeutics to be Possible Value Trap.

Key valuation signals for OVID:

  • Shiller PE Ratio:
  • GF Value™: $13.57 vs. price of $2.62 (80.7% below fair value)
  • GF Score™: 48/100 with 4 warning signs

No single metric tells the full story. See the OVID stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Ovid Therapeutics Business Description

Other Exchanges 1OT:Germany
Address 441 Ninth Avenue, 14th Floor, New York, NY, USA, 10001
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.
48GF Score

Get the complete analysis for OVID

Shiller PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.62
Price
$13.57
GF Value